This is a postdoc position for 1 year with possibility to extent for another 2 years (1+2). In this project you will identify novel immune checkpoints based on bioinformatics combined with a functional pipeline as future targets for cancer immune therapy. You will be responsible for the characterization of novel putative inhibitory receptors. You will generate recombinant protein, cells lines and novel antibodies with U-MAB to functionally study their role in anti-cancer responses.

We invite candidates with a PhD in Immunology, with a broad interest in immunological processes and affinity with receptor characterization to apply. Experience with antibody production, recombinant protein generation and in vitro immune assays is preferred. You are fluent in written and spoken English, and expected to write papers based on data gathered, and present these data on conferences.

Fixed-term contract: 1-3 years.

The maximum salary for this position (100%) is € 4.481,00 gross per month based on full-time employment (work week 36 hours). This job is based on a temporary position for One year with possibility to extent for another 2 years (1+2)..

In addition, we offer an annual benefit of 8.3%, holiday allowance, travel expenses and career opportunities. The terms of employment are in accordance with the Cao University Medical Centers (UMC).

Center for Translational Immunology

You will part of the Meyaard lab that is situated in Center for Translational Immunology, in the UMC Utrecht and is part of the Oncode Institute. This project is part of a larger tumor immunology collaboration between the Princes Maxima Center and the UMC Utrecht. At the Center for Translational Immunology, approximately 200 people study immune responses in all their facets. We have a state-of-the-art flow cytometry facility, imaging facility, protein facility and the antibody generation facility U-MAB, all set up to facilitate the best transitional research possible. In the Meyaard lab a dynamic and international team studies immune checkpoints in health and disease. Our basic research line focuses on identification and characterization of checkpoint receptors, their ligands and mechanism of action. We do this with a strong translational focus to apply our knowledge in the clinic to cure patients. To foster this goal, research in our group covers the complete spectrum from academic basic to translational research, as well as public-private collaborative research.